Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Enlivex ( (ENLV) ) is now available.
On February 3, 2026, Enlivex Therapeutics Ltd. held an Extraordinary General Meeting of Shareholders in Israel, where investors approved a proposal to change the company’s name to Enlivex Ltd. The change underscores a streamlining of the corporate brand while maintaining continuity for shareholders in the U.S. and Israeli markets.
The Israeli Registrar of Companies issued the formal Certificate of Change of Name on February 10, 2026, making the new name legally effective from that date. The company has since updated its U.S. securities filings to reflect the new name, aligning its regulatory documentation and market identity across jurisdictions without altering its underlying operations.
The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is held down mainly by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite improvement) and a valuation profile dominated by negative earnings. Technicals provide partial support due to a clear uptrend, but overbought momentum readings add near-term risk.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd. is an Israel-based biopharmaceutical company formerly known as Enlivex Therapeutics Ltd., focused on developing immunotherapy treatments. The company is listed in the United States as a foreign private issuer and files annual reports under Form 20-F, reflecting its access to U.S. capital markets and global investor base.
Average Trading Volume: 4,180,479
Technical Sentiment Signal: Strong Sell
Current Market Cap: $265.9M
For a thorough assessment of ENLV stock, go to TipRanks’ Stock Analysis page.